Phase I Clinical Trial of TO-203 - Safety Trial in Patients with HDM (House Dust Mite)-induced Asthma -

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221584

Enrollment

Registered

2011-09-15

Start date

2011-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HDM-induced asthma

Interventions

investigational material(s) Generic name etc : TO-203 INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Positive specific IgE against HDM (>=IgE Class 3) 2) Positive HDM-allergen scratch test

Exclusion criteria

Exclusion criteria: 1) A clinical history of perennial allergic asthma and/or rhinitis caused by an allergen to which the patient is regularly exposed, and sensitised (except HDM) 2) Previous treatment by immunotherapy with HDM

Design outcomes

Primary

Measure	Time frame
Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026